阿司匹林与大剂量静注人免疫球蛋白联合治疗小儿川崎病的临床效果

Clinical Effect of Aspirin Combined with High-dose Human Immunoglobulin for Intravenous Injection in the Treatment of Kawasaki Disease in Children

目的:探讨阿司匹林与大剂量静注人免疫球蛋白联合治疗小儿川崎病的临床效果。方法:选择2020年1月—2022年6月龙岩市第二医院收治的50例川崎病患儿为研究对象,依据随机抽签法将其分为对照组和观察组,各25例。两组均予以同等剂量的阿司匹林治疗,对照组予以常规剂量静注人免疫球蛋白联合治疗,观察组予以大剂量静注人免疫球蛋白联合治疗。比较两组临床治疗效果,症状消失时间、住院时间,治疗前后血清炎症因子水平及血清脑利钠肽(BNP)水平。结果:观察组治疗总有效率为96.00%,高于对照组76.00%,差异有统计学意义(P<0.05)。观察组淋巴结肿大消失时间、发热消失时间、手足肿胀消失时间、黏膜充血消失时间早于对照组,住院时间短于对照组,差异有统计学意义(P<0.05)。两组治疗前血清炎症因子水平比较,差异无统计学意义(P>0.05);观察组治疗后白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组BNP水平比较,差异无统计学意义(P>0.05);治疗后,两组BNP水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论:阿司匹林与大剂量静注人免疫球蛋白联合治疗小儿川崎病的临床效果显著,能有效缩短症状消失时间、住院时间,改善血清炎症因子水平及BNP水平,利于病症进一步好转。

Objective:To explore the clinical effect of Aspirin combined with high-dose Human Immunoglobulin for Intravenous Injection in the treatment of Kawasaki disease in children.Method:A total of 50 children with Kawasaki disease who admitted to the Second Hospital of Longyan from January 2020 to June 2022 were selected as the research subjects.They were randomly divided into the control group and the observation group based on the method of drawing lots,25 cases in each group.Two groups were treated with the same dose of Aspirin,the control group was treated with conventional-dose Human Immunoglobulin for Intravenous Injection combination therapy,and the observation group was treated with high-dose Human Immunoglobulin for Intravenous Injection combination therapy.The clinical treatment efficacy,symptom disappearance time,hospitalization time,serum inflammatory factor levels and serum brain natriuretic peptide(BNP)level before and after treatment between two groups were compared.Result:The total effective rate in the observation group was 96.00%,which was higher than 76.00%in the control group,the difference was statistically significant(P<0.05).The disappearance times of lymph node enlargement,fever,hand and foot swelling,mucosal congestion were earlier than those of the control group,and hospitalization time of the observation group was shorter than that of the control group,the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant differences in serum inflammatory factor levels between two groups(P>0.05);after treatment,the levels of interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in BNP level between the groups of children(P>0.05);after treatment,the BNP levels in two groups decreased compared with those before treatment,and the BNP level in the observation group was lower than that in the control group,the differences were statistically significant(P<0.05).Conclusion:The combination of Aspirin and high-dose Human Immunoglobulin for Intravenous Injection has a significant clinical effect in the treatment of Kawasaki disease in children,it can effectively shorten the disappearance time of symptoms and hospitalization time,improve the level of serum inflammatory factors and serum BNP level,which is conducive to further improvement of the disease.